The prevalence of fungal infections has increased in immunocompromised patients, leading to millions of deaths annually. Arachidonic acid (AA) metabolites, such as eicosanoids, play important roles in regulating innate and adaptative immune function, particularly since they can function as virulence factors enhancing fungal colonization and are produced by mammalian and lower eukaryotes, such as yeasts and other fungi (
Candida albicans,
Histoplasma capsulatum and
Cryptococcus neoformans).
C. albicans produces prostaglandins (PG), Leukotrienes (LT) and Resolvins (Rvs), whereas the first two have been well documented in
Cryptococcus sp. and
H. capsulatum. In this review, we cover the eicosanoids produced by the host and fungi during fungal infections. These fungal-derived PGs have immunomodulatory functions analogous to their mammalian counterparts. Prostaglandin E
2 (PGE
2) protects
C. albicans and
C. parapsilosis cells from the phagocytic and killing activity of macrophages.
H. capsulatum PGs augment the fungal burden and host mortality rates in histoplasmosis. However, PGD
2 potentiates the effects and production of LTB
4, which is a very potent neutrophil chemoattractant that enhances host responses. Altogether, these data suggest that eicosanoids, mainly PGE
2, may serve as a new potential target to combat diverse fungal infections.
View Full-Text
►▼
Show Figures
This is an open access article distributed under the
Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited